Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 11/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 11/20 | 0.73 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.73 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1235445 | 0.87 | CHRM3 (0.65) | CHRM2CHRM1CHRM3CHRM4CYP2C19 | |
| SCHEMBL1234853 | 0.85 | CHRM3 (0.63) | CHRM2CHRM1CHRM3CHRM4CYP2C19 | |
| SCHEMBL9878642 | 0.84 | CHRM2 (0.63) | CHRM2CHRM1CHRM3CHRM4KCNH2 | |
| SCHEMBL4251203 | 0.83 | CHRM3 (0.53) | CHRM2CHRM1CHRM3CHRM4ALDH1A1 | |
| Penthienate SCHEMBL31393386 | 0.83 | CHRM1 (0.68) | CHRM2CHRM1CHRM3CHRM4KCNH2 | |
| Penthienate SCHEMBL250881 | 0.82 | CHRM1 (0.67) | CHRM2CHRM1CHRM3CHRM4KCNH2 | |
| SCHEMBL14940262 | 0.82 | CHRM3 (0.64) | CHRM2CHRM1CHRM3CHRM4KCNH2 | |
| Hydrochloric Acid SCHEMBL9878774 | 0.81 | CHRM2 (0.71) | CHRM2CHRM1CHRM3CHRM4KCNH2 | |
| SCHEMBL9877278 | 0.81 | CHRM2 (0.71) | CHRM2CHRM1CHRM3CHRM4KCNH2 | |
| SCHEMBL14408507 | 0.81 | CHRM3 (0.58) | CHRM2CHRM1CHRM3CHRM4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084463-B2 | Quinuclidine derivatives and their use as muscarinic M3 receptor antagonists | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| EP-1811999-B1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| EP-2206499-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-20100168132-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PRESS NEIL JOHN | 2010-07-01 | — | — | US | disclosed |
| US-7723356-B2 | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists | NOVARTIS AG (CH) | 2010-05-25 | — | — | US | disclosed |
| US-20090048281-A1 | (R)-3-(2-Cyclohexyl-2-hydroxy-2-phenyl-acetoxy)-1-(isoxazol-3-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2] octane, useful for treating inflammatory or obstructive airways diseases | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | disclosed |
| EP-1811999-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006048225-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048281-A1 | (R)-3-(2-Cyclohexyl-2-hydroxy-2-phenyl-acetoxy)-1-(isoxazol-3-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2] octane, useful for treating inflammatory or obstructive airways diseases | CHRM3, CHRM2, CHRM1 | CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885 |
| US-20100168132-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM1 | CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.